Impact of an Anti-Microbial Stewardship Program on Targeted Antimicrobial Therapy in a Tertiary Care Health Care Institute in Central India.
amsp
antimicrobial stewardship program
bacterial culture rate
point prevalence survey (pps)
targeted therapy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
accepted:
05
10
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Introduction Antimicrobial resistance (AMR) has become a global pandemic. In order to identify this menace, World Health Organisation (WHO) has developed the Global Action Plan on AMR (GAP AMR). Antimicrobial stewardship programs (AMSP) have been identified as a decisive tool for combating AMR. One of the most efficient measures of these programs has been the implementation of point prevalence surveys (PPS) of antibiotic usage and subsequent audit feedback. The present study was undertaken to identify the impact of AMSP on curtailing of empirical usage of antibiotics and the augmentation of targeted therapy. Methods It is an observational, cross-sectional study comprising 1396 patients. The microbiology culture details and anti-microbial-sensitivity results were recorded. Antibiotic prescriptions were recorded in each patient during their hospital stay. Result Out of 1396 patients treated over four quarters (Q1-Q4), 711 (50.9%) patients were on antibiotics, and among them, only 415 patients were subjected to any microbiological cultures with an overall bacterial culture rate (BCR) of 58.3%, and 296 patients (41.6%) were treated with antibiotics empirically without sending any samples for bacterial culture. There was a statistically significant rise in BCR from 47.3% in the first quarter to 77.6% in the fourth quarter. Sending specimens for blood culture increased significantly from 29.2% in Q1 to 37.6% in Q4. After receiving culture reports, 72.3% of cases continued with the same antibiotic, the antibiotic was changed in 19.9% of cases, and the antibiotic was stopped in 7.8% of cases. Conclusion There was a strong positive impact of AMSP in curtailment of empirical usage of antibiotics and augmenting targeted therapy as evidenced by the significant rise in BCR over Q1-Q4 PPS as well as a significant rise in ordering for blood culture over the same time period.
Identifiants
pubmed: 34754675
doi: 10.7759/cureus.18517
pmc: PMC8568562
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e18517Informations de copyright
Copyright © 2021, Garg et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Family Med Prim Care. 2019 Jun;8(6):1828-1834
pubmed: 31334140
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
Intern Med J. 2012 Jun;42(6):719-21
pubmed: 22697156
BMC Infect Dis. 2020 Feb 3;20(1):102
pubmed: 32013908
PLoS One. 2013 Dec 23;8(12):e82785
pubmed: 24376580
Rev Argent Microbiol. 2011 Jul-Sep;43(3):203-11
pubmed: 22430995
JAC Antimicrob Resist. 2021 Apr 26;3(2):dlab047
pubmed: 33937773
J Hosp Med. 2016 May;11(5):336-40
pubmed: 26762577
Expert Rev Anti Infect Ther. 2020 Sep;18(9):897-910
pubmed: 32394754
J Glob Antimicrob Resist. 2020 Dec;23:315-320
pubmed: 33199265
BMC Fam Pract. 2017 Jan 26;18(1):9
pubmed: 28125965
Oman Med J. 2011 May;26(3):205-6
pubmed: 22043418
Ther Adv Drug Saf. 2014 Dec;5(6):229-41
pubmed: 25436105
JAC Antimicrob Resist. 2021 Feb 08;3(1):dlab008
pubmed: 34223086
PLoS One. 2019 Jan 2;14(1):e0208819
pubmed: 30601829
J Family Med Prim Care. 2021 Feb;10(2):991-997
pubmed: 34041110
Drugs. 2011 Apr 16;71(6):745-55
pubmed: 21504250
Ital J Pediatr. 2019 May 20;45(1):63
pubmed: 31109362
Indian J Med Res. 2017 Dec;146(6):683-687
pubmed: 29664025
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003543
pubmed: 23633313
Swiss Med Wkly. 2019 Oct 27;149:w20135
pubmed: 31656037
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Indian J Med Res. 2019 Feb;149(2):180-184
pubmed: 31219081
Am J Infect Control. 2016 Mar 1;44(3):332-9
pubmed: 26717869
J Antimicrob Chemother. 2018 Apr 1;73(4):844-851
pubmed: 29340609